Editor’s note: This is an automatically generated transcript. Please notify editor@healio.com if there are concerns regarding accuracy of the transcription. In general, the most common type of ...

C3.ai (AI 3.92%) developed a portfolio of 40 ready-made AI software applications that businesses can customize to suit their needs. These apps serve as a shortcut to AI adoption, and while they have ...

For over a decade, Ruth has written for multiple outlets providing patient education, including Health. She has written for health student education companies, collaborating on an anatomy textbook ...

C3 AI stock plunged 17% Thursday morning after the company missed third-quarter expectations and announced widespread layoffs. CEO Stephen Ehikian told shareholders that the company's cost structure ...

In this analysis of patients with myeloperoxidase-ANCA-positive AAV, all urinary complement C3 fragment levels were elevated significantly compared with healthy controls (P .01 for all). Specific ...

The complement system is an innate immune response that leads to increased inflammation. The drug pegcetacoplan—a complement inhibitor—was approved for medical use in the United States in 2021 to ...

Complement 3 glomerulopathy (C3G) is a rare kidney disease that affects your body’s innate immune system (complement system). Complement 3 glomerulopathy (C3G) is a kidney disease that’s caused by ...

Researchers from the Children's Hospital of Philadelphia (CHOP) and the Clinic for Special Children found that complement factor I (CFI) deficiency, an ultra-rare genetic disorder that can cause ...

C3 AI stock tanked after it announced preliminary financial results and a restructuring of its global sales and services organization. C3 AI said it expects to report revenue between $70.2 million and ...

Pegcetacoplan is the first FDA-approved treatment for C3G and primary IC-MPGN, targeting excessive C3 complement activation. The phase 3 VALIANT trial showed a 68% reduction in UPCR and stabilization ...

C3 AI founder and Chief Executive Officer Tom Siebel today announced that he will step down because of health issues. Shares of the artificial intelligence company closed 11% lower on the news. In a ...

ARO-C3 treatment led to deep and sustained reductions in alternative pathway complement activity and proteinuria. ARO-C3, an investigational RNA interference-based therapy targeting hepatic expression ...